2-溴-3-羟基-6-甲基吡啶 | 23003-35-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-3-羟基-6-甲基吡啶
• 中文别名: 2-溴-6-甲基-3-羟基吡啶；2-溴-6-甲基-吡啶-3-醇
• 英文名称: 2-bromo-3-hydroxy-6-methylpyridine
• 英文别名: 2-bromo-6-methylpyridin-3-ol；2-Brom-3-hydroxy-6-methylpyridin
• CAS: 23003-35-2
• 化学式: C₆H₆BrNO
• mdl: MFCD06655956
• 分子量: 188.024
• InChiKey: UHMANLXCLQNQJD-UHFFFAOYSA-N

物化性质

• 熔点：
  186-187 °C
• 沸点：
  311.8±37.0 °C(Predicted)
• 密度：
  1.655±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-3-hydroxy-6-methylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-3-hydroxy-6-methylpyridine
CAS number: 23003-35-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6BrNO
Molecular weight: 188

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-3-羟基-6-甲基吡啶 在 4-二甲氨基吡啶 、 aluminum (III) chloride 、 potassium permanganate 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 生成 6-溴-5-羟基-2-吡啶羧酸甲酯
  参考文献：
  名称：

  [EN] DI-MACROCYCLES
  [FR] DI-MACROCYCLES

  摘要：

  这项发明涉及可用于治疗和诊断应用的化合物和复合物。

  公开号：

  WO2014078690A1
• 作为产物：
  描述：

  3-羟基-6-甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 生成 2-溴-3-羟基-6-甲基吡啶
  参考文献：
  名称：

  Efficient Regioselective Preparationof Monobromo and Bromoiodo Hydroxy Pyridines from Dibromoderivativesvia Bromine-Lithium Exchange

  摘要：

  氢氧嘧啶的环状二溴化反应采用NBS在乙腈中进行，随后与RLi进行溴锂交换，最后用H2O或I2捕获，完全区域选择性地得到了单溴和溴碘衍生物。用NIS对溴氢氧嘧啶进行碘化反应也是完全区域选择性的。

  DOI：

  10.1055/s-2003-41013
• 作为试剂：
  描述：

  3-羟基-6-甲基吡啶 、 溴 在 氮气 、 2-溴-3-羟基-6-甲基吡啶 作用下， 以 氢溴酸 、 溶剂黄146 为溶剂， 反应 8.0h， 生成 2-溴-3-羟基-6-甲基吡啶
  参考文献：
  名称：

  Bipyridyls and their use as inks

  摘要：

  使用联吡啶作为油墨的工艺，其一般公式为 ##STR1## 其中R，R'例如是烷基，而R.sup.1，R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6例如是氢或烷基基团，或者R.sup.1和R.sup.2或R.sup.2和R.sup.3，以及/或者R.sup.4和R.sup.5或R.sup.5和R.sup.6与吡啶环结合形成异喹啉或喹啉环系统。

  公开号：

  US05266700A1

文献信息

• [EN] ROR-GAMMA INHIBITORS<br/>[FR] INHIBITEURS DE ROR-GAMMA
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019063748A1

  公开（公告）日：2019-04-04

  The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

  本发明涉及公式I的化合物和包含公式I化合物的药物组合物。公式I的化合物在治疗由RORγ介导的炎症性、代谢性或自身免疫性疾病方面是有用的。
• Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
  申请人：——

  公开号：US20030083357A1

  公开（公告）日：2003-05-01

  The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

  本发明涉及Formula (I)的化合物，可能在治疗疾病，如代谢紊乱、血脂异常和/或高胆固醇血症方面有用：
• Heterocyclic derivatives for the treatment of diabetes and other diseases
  申请人：Maxia Pharmaceuticals, Inc.

  公开号：US06515003B1

  公开（公告）日：2003-02-04

  The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.

  本发明涉及某些Formula (I)的取代杂环，这些取代杂环在治疗与脂质和碳水化合物代谢相关的疾病方面很有用，如2型糖尿病、脂肪细胞分化、不受控制的增殖，如淋巴瘤、霍奇金病、白血病、乳腺癌、前列腺癌或一般癌症；以及炎症，如骨关节炎、类风湿关节炎、克罗恩病或炎症性肠病。
• [EN] MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] MODULATEURS D'INDOLAMINE 2,3-DIOXYGÉNASE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019003148A1

  公开（公告）日：2019-01-03

  Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. Formula (I):

  提供了公式I的IDO抑制剂化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们在预防和/或治疗疾病中的使用方法。公式（I）:
• COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  申请人：WHITTEN Jeffrey P.

  公开号：US20120316182A1

  公开（公告）日：2012-12-13

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物调节储存操作钙（SOC）通道的活性。本文还描述了使用这种SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或症状。